First Hawaiian Bank Invests $2.08 Million in Natera, Inc. (NASDAQ:NTRA)

First Hawaiian Bank bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 19,218 shares of the medical research company’s stock, valued at approximately $2,081,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quent Capital LLC increased its holdings in Natera by 3.2% in the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after buying an additional 99 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Arcadia Investment Management Corp MI lifted its position in Natera by 47.8% during the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after buying an additional 174 shares in the last quarter. Fifth Third Bancorp lifted its position in Natera by 3.0% during the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after buying an additional 179 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group lifted its position in Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Trading Down 1.7 %

Shares of NASDAQ:NTRA traded down $1.71 during midday trading on Monday, hitting $97.91. 1,121,618 shares of the stock were exchanged, compared to its average volume of 1,382,295. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of -31.38 and a beta of 1.48. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The business’s 50-day moving average price is $108.39 and its 200 day moving average price is $94.05. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $117.23.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. The company had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm’s quarterly revenue was up 52.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.23) earnings per share. Analysts predict that Natera, Inc. will post -2.43 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Daniel Rabinowitz sold 30,000 shares of Natera stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $104.59, for a total value of $3,137,700.00. Following the transaction, the insider now directly owns 204,495 shares of the company’s stock, valued at $21,388,132.05. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total value of $185,946.90. Following the transaction, the chief financial officer now directly owns 71,955 shares of the company’s stock, valued at $7,170,315.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel Rabinowitz sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $104.59, for a total value of $3,137,700.00. Following the completion of the transaction, the insider now directly owns 204,495 shares in the company, valued at $21,388,132.05. The disclosure for this sale can be found here. Insiders have sold a total of 118,387 shares of company stock valued at $12,684,836 over the last ninety days. 7.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on NTRA shares. Jefferies Financial Group started coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 target price on the stock. The Goldman Sachs Group increased their target price on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Robert W. Baird increased their target price on Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. TD Cowen raised their price target on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Finally, Craig Hallum initiated coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $103.27.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.